Supernus Pharmaceuticals (NASDAQ:SUPN) Given New $87.00 Price Target at Cantor Fitzgerald

Supernus Pharmaceuticals (NASDAQ:SUPN) had its target price hoisted by equities researchers at Cantor Fitzgerald from $67.00 to $87.00 in a report issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald‘s price objective would suggest a potential upside of 209.06% from the stock’s current price.

Several other equities analysts have also issued reports on SUPN. Piper Sandler initiated coverage on shares of Supernus Pharmaceuticals in a report on Wednesday. They issued an “overweight” rating and a $47.00 price target for the company. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings lowered Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a report on Friday. Finally, Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $63.50.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $28.15 on Wednesday. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -36.56, a PEG ratio of 1.19 and a beta of 0.52. The company’s 50 day simple moving average is $42.08 and its 200 day simple moving average is $47.15. Supernus Pharmaceuticals has a fifty-two week low of $27.97 and a fifty-two week high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.14). The firm had revenue of $208.60 million during the quarter, compared to the consensus estimate of $217.56 million. Supernus Pharmaceuticals had a negative net margin of 5.07% and a positive return on equity of 12.99%. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.80) EPS. As a group, analysts predict that Supernus Pharmaceuticals will post 1.89 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SUPN. Pictet Asset Management Holding SA lifted its stake in Supernus Pharmaceuticals by 0.6% in the 3rd quarter. Pictet Asset Management Holding SA now owns 434,915 shares of the specialty pharmaceutical company’s stock valued at $19,116,000 after acquiring an additional 2,437 shares in the last quarter. CenterBook Partners LP bought a new position in shares of Supernus Pharmaceuticals during the 3rd quarter worth approximately $876,000. Heritage Family Offices LLP bought a new position in shares of Supernus Pharmaceuticals during the 3rd quarter worth approximately $39,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Supernus Pharmaceuticals in the third quarter valued at approximately $128,000. Finally, Profund Advisors LLC raised its holdings in shares of Supernus Pharmaceuticals by 351.2% in the third quarter. Profund Advisors LLC now owns 39,129 shares of the specialty pharmaceutical company’s stock valued at $1,684,000 after purchasing an additional 30,456 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.